CIPH Ciphergen Biosystems (MM)

Ciphergen Announces Issuance of Patent for Multi-marker Diagnostics Using SELDI ProteinChip(R) Technology Complements Existing Patents Covering Ciphergen's Pattern Track(TM) Biomarker Discovery to Assay Process FREMONT, Calif., May 18 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH) announced today that it has been granted U.S. Patent 6,844,165, directed to the detection of multiple diagnostic markers by SELDI-TOF-MS for the diagnosis of disease. Multi-marker assays using Ciphergen's patented SELDI ProteinChip(R) System are the basis for the clinical diagnostic tests that Ciphergen Diagnostics is currently developing for commercialization. Ciphergen has several issued United States patents that cover aspects of our integrated Pattern Track(TM) biomarker discovery, validation and assay process. These include U.S. patent 5,719,060, which covers the basic SELDI process; U.S. patents 6,225,047 and 6,579,719, which cover biomarker discovery through protein profile difference mapping using SELDI; U.S. patent 6,675,104, which covers pattern proteomics based discovery, validation and classification of biomarker combinations (multi-markers) using a multivariate pattern recognition algorithm; and this new patent (6,844,165), which covers multi-marker diagnostic assays performed on the SELDI platform. "We believe combinations of specific, identified protein biomarkers can provide greater predictive diagnostic value than a single biomarker," said William E. Rich, President and CEO of Ciphergen. "Ciphergen's family of ProteinChip technology patents form a powerful portfolio supporting our leadership position in biomarker proteomics, enabling Ciphergen to continue as the premier innovator in translating pattern-based biomarker discovery to multi-marker-based diagnostics through our Pattern Track(TM) process." About Ciphergen Ciphergen's Diagnostics Division is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Centers(R) for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen's Biosystems Division develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research, and process proteomics applications. ProteinChip Systems enable protein discovery, characterization, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the diagnostic tests that Ciphergen Diagnostics is developing, the predictive diagnostic value of protein biomarkers, possible improvements to assay performance through SELDI-based assays, and the expectation that protein multi-marker tests will improve patient care. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including ProteinChip technology's ability to successfully discover, validate and assay biomarkers and patterns of biomarkers that are highly predictive and therefore meet with customer acceptance, and our ability to protect and promote our proprietary technologies. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-Q dated May 10, 2005, for further information regarding these and other risks of the Company's business. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers of Ciphergen Biosystems, Inc., +1-510-505-2233 Web site: http://www.ciphergen.com/

Copyright